- Home
- ROIV vs OLED Comparison
ROIV vs OLED Comparison
Compare ROIV & OLED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- OLED
- Stock Information
- Founded
- ROIV 2014
- OLED 1985
- Country
- ROIV United Kingdom
- OLED United States
- Employees
- ROIV N/A
- OLED N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- OLED Semiconductors
- Sector
- ROIV Health Care
- OLED Technology
- Exchange
- ROIV Nasdaq
- OLED Nasdaq
- Market Cap
- ROIV 8.6B
- OLED 7.4B
- IPO Year
- ROIV N/A
- OLED 1992
- Fundamental
- Price
- ROIV $15.28
- OLED $136.44
- Analyst Decision
- ROIV Strong Buy
- OLED Strong Buy
- Analyst Count
- ROIV 4
- OLED 7
- Target Price
- ROIV $15.50
- OLED $190.43
- AVG Volume (30 Days)
- ROIV 7.8M
- OLED 583.1K
- Earning Date
- ROIV 11-11-2025
- OLED 10-29-2025
- Dividend Yield
- ROIV N/A
- OLED 1.32%
- EPS Growth
- ROIV N/A
- OLED 9.88
- EPS
- ROIV N/A
- OLED 5.12
- Revenue
- ROIV $23,233,000.00
- OLED $661,991,000.00
- Revenue This Year
- ROIV N/A
- OLED $6.28
- Revenue Next Year
- ROIV $281.14
- OLED $10.49
- P/E Ratio
- ROIV N/A
- OLED $26.58
- Revenue Growth
- ROIV N/A
- OLED 6.23
- 52 Week Low
- ROIV $8.73
- OLED $103.70
- 52 Week High
- ROIV $16.05
- OLED $215.90
- Technical
- Relative Strength Index (RSI)
- ROIV 82.00
- OLED 41.41
- Support Level
- ROIV $13.81
- OLED $133.44
- Resistance Level
- ROIV $14.48
- OLED $138.50
- Average True Range (ATR)
- ROIV 0.47
- OLED 4.09
- MACD
- ROIV 0.22
- OLED -0.36
- Stochastic Oscillator
- ROIV 81.67
- OLED 21.32
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About OLED Universal Display Corporation
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.